Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200214390> ?p ?o ?g. }
- W4200214390 endingPage "6225" @default.
- W4200214390 startingPage "6225" @default.
- W4200214390 abstract "Detection of ovarian cancer (OC) circulating tumour cells (CTCs) is primarily based on targeting epithelial markers, thus failing to detect mesenchymal tumour cells. More importantly, the immune checkpoint inhibitor marker PD-L1 has not been demonstrated on CTCs from OC patients. An antibody staining protocol was developed and tested using SKOV-3 and OVCA432 OC cell lines. We targeted epithelial (cytokeratin (CK) and EpCAM), mesenchymal (vimentin), and OC-specific (PAX8) markers for detection of CTCs, and CD45/16 and CD31 were used for the exclusion of white blood and vascular endothelial cells, respectively. PD-L1 was used for CTC characterisation. CTCs were enriched using the Parsortix™ system from 16 OC patients. Results revealed the presence of CTCs in 10 (63%) cases. CTCs were heterogeneous, with 113/157 (72%) cells positive for CK/EpCAM (epithelial marker), 58/157 (37%) positive for vimentin (mesenchymal marker), and 17/157 (11%) for both (hybrid). PAX8 was only found in 11/157 (7%) CTCs. In addition, 62/157 (39%) CTCs were positive for PD-L1. Positivity for PD-L1 was significantly associated with the hybrid phenotype when compared with the epithelial (p = 0.007) and mesenchymal (p = 0.0009) expressing CTCs. Characterisation of CTC phenotypes in relation to clinical outcomes is needed to provide insight into the role that epithelial to mesenchymal plasticity plays in OC and its relationship with PD-L1." @default.
- W4200214390 created "2021-12-31" @default.
- W4200214390 creator A5005231347 @default.
- W4200214390 creator A5011046362 @default.
- W4200214390 creator A5027775730 @default.
- W4200214390 creator A5039297886 @default.
- W4200214390 creator A5046795863 @default.
- W4200214390 creator A5048490043 @default.
- W4200214390 creator A5053472136 @default.
- W4200214390 creator A5054900690 @default.
- W4200214390 creator A5065550700 @default.
- W4200214390 creator A5070240933 @default.
- W4200214390 creator A5072379739 @default.
- W4200214390 creator A5073719611 @default.
- W4200214390 creator A5080731456 @default.
- W4200214390 date "2021-12-10" @default.
- W4200214390 modified "2023-10-06" @default.
- W4200214390 title "Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients" @default.
- W4200214390 cites W1805581579 @default.
- W4200214390 cites W1881020575 @default.
- W4200214390 cites W1975582311 @default.
- W4200214390 cites W1987548000 @default.
- W4200214390 cites W1995692874 @default.
- W4200214390 cites W1996863944 @default.
- W4200214390 cites W2065036320 @default.
- W4200214390 cites W2070291618 @default.
- W4200214390 cites W2082239705 @default.
- W4200214390 cites W2085896576 @default.
- W4200214390 cites W2086509569 @default.
- W4200214390 cites W2115596977 @default.
- W4200214390 cites W2116483002 @default.
- W4200214390 cites W2119764457 @default.
- W4200214390 cites W2138690899 @default.
- W4200214390 cites W2159703296 @default.
- W4200214390 cites W2165212740 @default.
- W4200214390 cites W2256481109 @default.
- W4200214390 cites W2284393155 @default.
- W4200214390 cites W2289256168 @default.
- W4200214390 cites W2441743520 @default.
- W4200214390 cites W2521705727 @default.
- W4200214390 cites W2522277066 @default.
- W4200214390 cites W2542902320 @default.
- W4200214390 cites W2592948192 @default.
- W4200214390 cites W2597703292 @default.
- W4200214390 cites W2626372827 @default.
- W4200214390 cites W2733241909 @default.
- W4200214390 cites W2748589525 @default.
- W4200214390 cites W2749326421 @default.
- W4200214390 cites W2760881075 @default.
- W4200214390 cites W2768516866 @default.
- W4200214390 cites W2782217647 @default.
- W4200214390 cites W2791753645 @default.
- W4200214390 cites W2796046027 @default.
- W4200214390 cites W2804512503 @default.
- W4200214390 cites W2804957255 @default.
- W4200214390 cites W2811473258 @default.
- W4200214390 cites W2885830696 @default.
- W4200214390 cites W2891998221 @default.
- W4200214390 cites W2893388531 @default.
- W4200214390 cites W2901533874 @default.
- W4200214390 cites W2905807945 @default.
- W4200214390 cites W2907642939 @default.
- W4200214390 cites W2908788147 @default.
- W4200214390 cites W2914335731 @default.
- W4200214390 cites W2917102036 @default.
- W4200214390 cites W2917476978 @default.
- W4200214390 cites W2945153242 @default.
- W4200214390 cites W2951013387 @default.
- W4200214390 cites W2953190001 @default.
- W4200214390 cites W2979359612 @default.
- W4200214390 cites W2983952571 @default.
- W4200214390 cites W2994290391 @default.
- W4200214390 cites W2994505596 @default.
- W4200214390 cites W3005106264 @default.
- W4200214390 cites W3006276296 @default.
- W4200214390 cites W3006466189 @default.
- W4200214390 cites W3021670556 @default.
- W4200214390 cites W3114417873 @default.
- W4200214390 cites W3119536057 @default.
- W4200214390 cites W3133581899 @default.
- W4200214390 cites W3138637670 @default.
- W4200214390 cites W3192923589 @default.
- W4200214390 doi "https://doi.org/10.3390/cancers13246225" @default.
- W4200214390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34944844" @default.
- W4200214390 hasPublicationYear "2021" @default.
- W4200214390 type Work @default.
- W4200214390 citedByCount "7" @default.
- W4200214390 countsByYear W42002143902022 @default.
- W4200214390 countsByYear W42002143902023 @default.
- W4200214390 crossrefType "journal-article" @default.
- W4200214390 hasAuthorship W4200214390A5005231347 @default.
- W4200214390 hasAuthorship W4200214390A5011046362 @default.
- W4200214390 hasAuthorship W4200214390A5027775730 @default.
- W4200214390 hasAuthorship W4200214390A5039297886 @default.
- W4200214390 hasAuthorship W4200214390A5046795863 @default.
- W4200214390 hasAuthorship W4200214390A5048490043 @default.
- W4200214390 hasAuthorship W4200214390A5053472136 @default.
- W4200214390 hasAuthorship W4200214390A5054900690 @default.